๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

17 recruiting trials

for Non-Small Cell Lung Cancer With HER2- Mutations

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites๐Ÿ“ Newport Beach๐Ÿ“ San Diego๐Ÿ“ San Francisco Bayer ยท Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations NCT06430437Phase 31 site๐Ÿ“ Shanghai Jiangsu HengRui Medicine Co., Ltd. ยท Tests: SHR-A1811, PD-1/PD-L1 inhibitorsใ€Pemetrexed/ Paclitaxelใ€Carboplatin/ Cisplatin A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors NCT07361562Phase 115 sites๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale๐Ÿ“ New Haven Cogent Biosciences, Inc. ยท Tests: CGT4255 Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients NCT05532696Phase 1, Phase 25 sites๐Ÿ“ Taichung๐Ÿ“ Tainan๐Ÿ“ Taipei Anbogen Therapeutics, Inc. ยท Tests: ABT-101 Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression NCT06749860Phase 21 site๐Ÿ“ Shanghai Shanghai Pulmonary Hospital, Shanghai, China ยท Tests: Disitamab Vedotin + tislelizumab + bevacizumab Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations NCT07195695Phase 3202 sites๐Ÿ“ Fresno๐Ÿ“ Glendale๐Ÿ“ Orange Boehringer Ingelheim ยท Tests: Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN) NCT06809764n/a36 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Daiichi Sankyo ยท Tests: No drug First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) NCT05099172Phase 1, Phase 294 sites๐Ÿ“ Gilbert๐Ÿ“ Duarte๐Ÿ“ Atlanta Bayer ยท Tests: BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3 Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC NCT05681780Phase 11 site๐Ÿ“ Tampa H. Lee Moffitt Cancer Center and Research Institute ยท Tests: Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations NCT06043817Phase 1, Phase 225 sites๐Ÿ“ Duarte๐Ÿ“ Huntington Beach๐Ÿ“ Irvine Pierre Fabre Medicament ยท Tests: STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels), STX-721/PFL-721 (RP2D) A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations NCT06706076Phase 1, Phase 242 sites๐Ÿ“ Phoenix๐Ÿ“ Irvine๐Ÿ“ La Jolla BlossomHill Therapeutics ยท Tests: BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed, BH-30643 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites๐Ÿ“ Irvine๐Ÿ“ La Jolla๐Ÿ“ Los Angeles PMV Pharmaceuticals, Inc ยท Tests: rezatapopt, pembrolizumab Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab NCT07486817Phase 217 sites๐Ÿ“ St Leonards๐Ÿ“ Malvern๐Ÿ“ Murdoch Boehringer Ingelheim ยท Tests: Zongertinib, Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab A Phase 1/1b Study of IAM1363 in HER2 Cancers NCT06253871Phase 153 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Aurora Iambic Therapeutics, Inc ยท Tests: IAM1363 Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer NCT07436858Phase 11 site๐Ÿ“ Amsterdam The Netherlands Cancer Institute ยท Tests: PET imaging with โธโนZr-trastuzumab, Blood sampling for pharmacokinetics A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors NCT05150691Phase 1, Phase 2102 sites๐Ÿ“ Cerritos๐Ÿ“ Los Angeles๐Ÿ“ San Diego DualityBio Inc. ยท Tests: DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775Phase 144 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) ยท Tests: BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy